[go: up one dir, main page]

BRPI0408136A - derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda - Google Patents

derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda

Info

Publication number
BRPI0408136A
BRPI0408136A BRPI0408136-6A BRPI0408136A BRPI0408136A BR PI0408136 A BRPI0408136 A BR PI0408136A BR PI0408136 A BRPI0408136 A BR PI0408136A BR PI0408136 A BRPI0408136 A BR PI0408136A
Authority
BR
Brazil
Prior art keywords
nitrogen
containing heterocyclic
disubstituted
heterocyclic derivatives
styryl
Prior art date
Application number
BRPI0408136-6A
Other languages
English (en)
Inventor
Kazumi Kikuchi
Makoto Oku
Jiro Fujiyasu
Norio Asai
Toshihiro Watanabe
Yukinori Nagakura
Hiroshi Tomiyama
Motoharu Sonegawa
Kazuo Tokuzaki
Yoshinori Iwai
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of BRPI0408136A publication Critical patent/BRPI0408136A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS HETEROCìCLICOS CONTENDO NITROGêNIO TENDO ESTIRILA 2,6-DISSUBSTITUìDA". A presente invenção refere-se a um novo derivado heterocíclico contendo nitrogênio tendo estirila 2,6-dissubstituída e um sal farmaceuticamente aceitável do mesmo, e uma composição farmacêutica compreendendo o derivado heterocíclico contendo nitrogênio e um sal farmaceuticamente aceitável do mesmo, em particular, uma composição farmacêutica eficaz como um inibidor do canal de sódio, tendo uma excelente ação analgésica, especialmente sobre a dor neuropática, com efeitos colaterais minimizados.
BRPI0408136-6A 2003-03-07 2004-03-05 derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda BRPI0408136A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003061758 2003-03-07
PCT/JP2004/002842 WO2004078715A1 (ja) 2003-03-07 2004-03-05 ２，６－ジ置換スチリルを有する含窒素へテロ環誘導体

Publications (1)

Publication Number Publication Date
BRPI0408136A true BRPI0408136A (pt) 2006-03-01

Family

ID=32958970

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408136-6A BRPI0408136A (pt) 2003-03-07 2004-03-05 derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda

Country Status (13)

Country Link
US (1) US8044206B2 (pt)
EP (1) EP1602645A4 (pt)
JP (1) JP4610480B2 (pt)
KR (1) KR20050114641A (pt)
CN (1) CN100516040C (pt)
AU (1) AU2004218115A1 (pt)
BR (1) BRPI0408136A (pt)
CA (1) CA2517081A1 (pt)
MX (1) MXPA05009290A (pt)
NO (1) NO20054607L (pt)
RU (1) RU2333200C2 (pt)
WO (1) WO2004078715A1 (pt)
ZA (1) ZA200507486B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100516040C (zh) 2003-03-07 2009-07-22 安斯泰来制药有限公司 具有2,6-二取代苯乙烯基的含氮杂环衍生物
US7432281B2 (en) 2003-10-07 2008-10-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP5025266B2 (ja) * 2004-09-01 2012-09-12 アステラス製薬株式会社 ピペリジン誘導体又はその製薬学的に許容される塩
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US20080300243A1 (en) * 2005-02-28 2008-12-04 Kelly Michael G Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same
BRPI0613505A2 (pt) * 2005-06-30 2011-01-11 Prosidion Ltd agonistas de gpcr
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
UY34244A (es) 2011-08-04 2013-02-28 Takeda Pharmaceutical Compuesto heterocíclico que contiene nitrógeno
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
DK3083616T3 (da) 2013-12-20 2021-08-30 Astex Therapeutics Ltd Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
EP3351528A1 (en) * 2014-02-14 2018-07-25 TOA Eiyo Ltd. Cyclic hydrocarbon compound
EP3277704A1 (en) 2015-03-31 2018-02-07 Allergan, Inc. Cyclosporins modified on the mebmt sidechain by heterocyclic rings
CN108503579B (zh) * 2018-03-28 2021-03-26 南京医科大学 芬太尼类似物及其应用
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658797A (en) 1968-08-06 1972-04-25 Lilly Co Eli Novel 5-nitroimidazole antiparasitic agents
GB2069481B (en) 1980-02-13 1983-07-27 Farmos Oy Substituted imidazole derivatives
GB2092569B (en) 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FR2522325B1 (fr) 1982-02-26 1985-08-09 Delalande Sa Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique
JPS60193966A (ja) * 1984-03-13 1985-10-02 Ss Pharmaceut Co Ltd Ν−ニコチノイルピペラジン誘導体及びその製造法
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
JPH0631230B2 (ja) 1987-02-20 1994-04-27 山之内製薬株式会社 飽和ヘテロ環カルボン酸アミド誘導体
JPH01316359A (ja) * 1988-03-23 1989-12-21 Idemitsu Kosan Co Ltd ピリジン誘導体および該誘導体を有効成分とする殺虫・殺ダニ剤
ES2096651T3 (es) 1990-06-07 1997-03-16 Merrell Pharma Inc Derivados de 1-piperidinil alcanoilarilsulfonamida.
JPH04342579A (ja) * 1991-05-20 1992-11-30 Hiroyoshi Hidaka １−アリールスルホニルピペラジン類及び薬剤として許容され得るその酸付加塩
JP3134552B2 (ja) * 1991-12-13 2001-02-13 宇部興産株式会社 シンナミルピペラジン誘導体、その製法及び農園芸用殺菌剤
EP0551617A3 (en) * 1991-12-13 1993-11-03 Ube Industries Cinnamyl piperazine derivatives method of manufacturing the same and agricultural/horticultural fungicides containing cinnamyl piperazine derivatives
US5240943A (en) 1991-12-19 1993-08-31 G. D. Searle & Co. Benzopyran class iii antiarrhythmic agents
GB9226111D0 (en) 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
WO1995024390A1 (en) 1994-03-11 1995-09-14 Smithkline Beecham Plc Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists
FR2726267B1 (fr) 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
DE69628333T2 (de) 1995-11-17 2004-04-08 Merck & Co., Inc. Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE19637237A1 (de) * 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
IL134168A0 (en) 1997-08-14 2001-04-30 Hoffmann La Roche Heterocyclic vinylethers against neurological disorders
US6410540B1 (en) 1998-08-28 2002-06-25 Scios, Inc. Inhibitors of p38-αkinase
EP1180513A4 (en) 1999-04-28 2002-07-10 Takeda Chemical Industries Ltd Cyclic amide compounds, process for the preparation of the same and uses thereof
PL354998A1 (en) 1999-07-28 2004-03-22 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
NZ520041A (en) 2000-01-20 2004-11-26 Eisai Co Ltd Novel piperidine compounds and drugs containing the same
JP4282048B2 (ja) * 2000-01-20 2009-06-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規ピペリジン化合物およびその医薬
WO2001074796A1 (en) 2000-03-31 2001-10-11 Bristol-Myers Squibb Pharma Company SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
HUP0400570A3 (en) 2000-12-04 2004-09-28 Hoffmann La Roche Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
NZ526741A (en) 2001-02-21 2004-04-30 Janssen Pharmaceutica Nv Isoxazoline derivatives as anti-depressants
EP1429767A1 (en) 2001-06-14 2004-06-23 Vertex Pharmaceuticals Incorporated Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
KR100864816B1 (ko) 2001-07-06 2008-10-23 니폰 가야꾸 가부시끼가이샤 색소증감 광전변환소자
WO2003013054A1 (en) 2001-07-17 2003-02-13 Sharp Kabushiki Kaisha Apparatus and method for generating data for detecting false alteration of encrypted data during processing
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
CN2562229Y (zh) * 2002-07-23 2003-07-23 昆山新力精密五金有限公司 散热器中的散热叶片之装置
WO2004011430A1 (ja) * 2002-07-25 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. ナトリウムチャネル阻害剤
WO2004037817A1 (ja) 2002-10-25 2004-05-06 Mitsubishi Pharma Corporation Ｎ−オキシド化合物
CN100516040C (zh) 2003-03-07 2009-07-22 安斯泰来制药有限公司 具有2,6-二取代苯乙烯基的含氮杂环衍生物
JP5025266B2 (ja) * 2004-09-01 2012-09-12 アステラス製薬株式会社 ピペリジン誘導体又はその製薬学的に許容される塩
JP4342579B2 (ja) 2006-08-31 2009-10-14 三洋電機株式会社 半導体装置

Also Published As

Publication number Publication date
CN1756740A (zh) 2006-04-05
JP4610480B2 (ja) 2011-01-12
KR20050114641A (ko) 2005-12-06
RU2333200C2 (ru) 2008-09-10
US20070099956A1 (en) 2007-05-03
AU2004218115A1 (en) 2004-09-16
MXPA05009290A (es) 2006-05-31
ZA200507486B (en) 2007-03-28
EP1602645A1 (en) 2005-12-07
US8044206B2 (en) 2011-10-25
NO20054607D0 (no) 2005-10-06
NO20054607L (no) 2005-12-06
JPWO2004078715A1 (ja) 2006-06-08
WO2004078715A1 (ja) 2004-09-16
CA2517081A1 (en) 2004-09-16
EP1602645A4 (en) 2008-12-03
CN100516040C (zh) 2009-07-22
RU2005131014A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
BRPI0408136A (pt) derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
SE0401342D0 (sv) Therapeutic compounds
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
TW200716628A (en) Novel compounds
CU23367A3 (es) Formulación de moxifloxacino con sal común
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
SE0402762D0 (sv) Indazole sulphonamide derivatives
PA8451801A1 (es) Derivados de la 9-oxima eritromicina
SE9900961D0 (sv) Novel compounds
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0012696A (pt) Composição oftálmica
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BR0314844A (pt) Novo composto
BRPI0408205A (pt) derivado de anilina substituìdo, composição farmacêutica, e, uso de uma composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.